Back

Cardiovascular events in patients treated with bempedoic acid vs. placebo: systematic review and meta-analysis

30 August 2024 (16:00 - 16:50)
Organised by: Logo
Congress Presentation Part of: Lipid-lowering therapies: new findings Drug therapy ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor David Mutschlechner

Mistelbach-Gaenserndorf Hospital, Mistelbach (Austria)

8 More presentations in this session

Presentation thumbnail
Rationale and design of the SHASTA-3 and SHASTA-4 studies: randomized, double-blind, placebo-controlled, phase 3 studies of plozasiran in patients with severe hypertriglyceridemia
Doctor D. Gaudet (Montreal, CA)
Abstract Slides Video
Presentation thumbnail
Changes in lipid lowering therapy one year after percutaneous coronary intervention: data from the large contemporary ZON-HR registry
Ms D. Peeters (Nijmegen, NL)
Abstract Slides Video
Presentation thumbnail
Association of lipid target achievement and cardiovascular outcomes following statin initiation: a population-based cohort study
Doctor J. Udell (Toronto, CA)
Abstract Slides Video
Presentation thumbnail
The impact of discontinuing proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors on clinical outcomes
Doctor H. Tsubata (Kyoto, JP)
Abstract Slides Video
Presentation thumbnail
Efficacy of lipid lowering therapy beyond statins to prevent cardiovascular events
Doctor I. Dykun (Essen, DE)
Abstract Slides Video

Access the full session

Session thumbnail
Lipid-lowering therapies: new findings

The Event

Event poster

ESC Congress 2024

30 August 2024 16:00 CET
You may be interested in
thumbnail
Congress Presentation
Real-world effectiveness of bempedoic acid therapy on the reduction of low-density lipoprotein cholesterol levels in Germany
thumbnail
Congress Presentation
How Bempedoic acid fits into oral combinations: unique mechanism and clinical impact
thumbnail
Congress Presentation
Pharmacological effects of bempedoic acid: clinical implications

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources